GET DAILY SIGNALSWhy Is CVS Health (CVS) Stock Down -11.17% Today?
Key Takeaways
- CVS shares fell 11.17% to $81.20, down from the prior session's close of $91.41.
- The primary catalyst was the company's announcement that it will split into two independent, publicly traded companies by the first half of 2028.
- The drop came despite third-quarter adjusted earnings of $2.09 per share, which handily beat the $1.65 consensus estimate.
- Investors weighed multi-year execution risk and structural challenges in retail pharmacy against the upbeat results and raised guidance.
- The move was company-specific: broader indexes traded higher, underscoring that the selloff was not driven by macro conditions.
- Traders are now watching for details on separation mechanics, cost allocation, and 2027 guidance execution.
- Explore Price Targets, Earnings, and Forecast pages for deeper analysis of CVS.
- Discover AI-driven trading strategies for this and thousands of other tickers on the Trending AI Robots page.
Opening Summary
CVS Health Corporation (CVS), the American healthcare giant that operates roughly 9,000 retail pharmacies alongside its Aetna insurance and Caremark pharmacy-benefit businesses, saw its stock plunge 11.17% on Wednesday. Shares closed the prior session at $91.41 and traded as low as $81.20 during the session, erasing a significant portion of the year's gains. The decline came even as the company delivered a strong third-quarter earnings beat and raised its full-year outlook, with markets instead reacting to a sweeping announcement that CVS will break itself apart into two separate companies.
Corporate Breakup Announcement
The dominant catalyst behind the market reaction was CVS's plan to split into two independent, publicly traded entities, a transaction it intends to complete in the first half of 2028 on a tax-free basis to shareholders. One company, retaining the CVS Health name, will house Aetna, Caremark, CVS Specialty, Oak Street Health, and Signify Health. The other, to be called CVS Pharmacy, will encompass the retail pharmacy network, mail pharmacy, MinuteClinic, and the Health100 technology platform.
Existing shareholders will receive shares in both companies upon completion. While management framed the move as a way to give each business greater strategic focus, financial flexibility, and operational agility, investors appeared to focus on the complexity and multi-year execution risk of unwinding a healthcare conglomerate assembled over two decades, including the landmark $78 billion acquisition of Aetna in 2018.
Strong Earnings Overshadowed by the Split
The selloff was notable because it unfolded against an otherwise impressive quarterly report. CVS reported third-quarter adjusted earnings of $2.09 per share, up 30.6% year over year and well above the $1.65 analysts had expected. Revenue climbed 5.4% to $108.4 billion, exceeding consensus of roughly $104.75 billion. The Health Care Benefits segment posted a sharp recovery in adjusted operating income, and the medical benefit ratio improved to 91.3% from 92.8% a year earlier.
Management also raised its fiscal 2026 adjusted earnings guidance to at least $8.20 per share, up from a prior range of $7.90 to $8.10, and lifted its revenue and operating cash flow outlook. The company forecast 2027 adjusted earnings of at least $8.65 per share, ahead of estimates. Yet the upbeat numbers were insufficient to offset concerns about the structural upheaval ahead.
Sector and Structural Concerns
Investor caution also reflects deeper industry pressures. Retail pharmacies face intensifying competition from online and mail-order rivals, while pharmacy-benefit managers contend with mounting regulatory and political scrutiny. Analysts have noted that vertical integration across insurance, pharmacy, and PBM businesses has drawn criticism over conflicts of interest and rising healthcare costs. By moving proactively, CVS may be positioning ahead of potential legislative or regulatory action, but the trade-off is a prolonged period of transition risk for shareholders.
Market Context and Trading Activity
The decline was driven overwhelmingly by company-specific news rather than broader market weakness. Major equity indexes traded higher on the day, highlighting that the selloff in CVS diverged from the wider tape. Volume was elevated well above typical levels as investors repriced the stock following the breakup disclosure, and the session's move pushed shares decisively below levels they had held through much of the recent quarter. The action carried the hallmarks of a "sell the news" event, with strong fundamentals and a confirmed split already partly anticipated after earlier media reports circulated.
What Comes Next for CVS
Looking ahead, investors will scrutinize the mechanics of the separation, including cost allocations, balance-sheet structuring, and dividend policies for the two successor companies. Attention will also remain on Aetna's Medicare Advantage performance, elevated medical cost trends, and the trajectory of the retail pharmacy business. Execution on the company's raised 2026 guidance and its 2027 outlook will be closely watched, as will any developments in the regulatory environment surrounding pharmacy-benefit managers. Until the separation is completed, CVS said it will continue operating as a single entity and delivering against its financial targets, leaving a multi-year runway of execution risk for the market to assess.
Trending AI Robots
Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that are currently demonstrating the strongest performance under prevailing market conditions. Tickeron offers hundreds of bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and the symbols they trade. Explore the page to see which AI-driven approaches are navigating today's market most effectively.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVS in +2.59% Uptrend, growing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CVS moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 160 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 24 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 48 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.467) is slightly lower than the industry average of (3.359). P/E Ratio (23.929) is within average values for comparable stocks, (126.681). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement